Business Update Positive

2026-10-08 09:34

- Fredun Pharmaceuticals is transforming into a brand-led healthcare platform focusing on pet healthcare, premium wellness, specialty therapeutics, and domestic generics. - Acquired a 26% stake in Goodman Vetcare (pet pharmacy) and Furlicks (pet wellness brand), alongside developing the WAGR pet-parenting platform. - Targeting a 100% branded portfolio by 2029 and aiming to double revenue and profitability over the next 3-4 years. - Expanding manufacturing capacity with a ~40,000 sq. ft. utility block at Palghar operational in October 2026. - Issued bonus shares in July 2026, increasing the equity base from 55.13 lakh to 1.65 crore shares.

Ownership Positive

2026-10-05 20:32

- Fredun Pharmaceuticals Ltd announced the allotment of 1,82,400 Equity Shares of face value Rs. 10/- each. - The shares were allotted upon the conversion of 60,800 warrants into equity shares following a 1:2 bonus issue adjustment. - Warrants were converted by 10 non-promoter and promoter allottees after paying the balance consideration.

Ownership Positive

2026-10-05 20:22

- Fredun Pharmaceuticals Ltd announced the allotment of 1,82,400 Equity Shares of face value Rs. 10/- each. - The shares were allotted upon conversion of 60,800 warrants into equity shares, adjusted for the 1:2 bonus issue. - Allotment made to non-promoter and promoter allottees on October 3, 2026. - Issue price was Rs. 1,250/- per warrant with balance consideration paid.

Ownership Positive

2026-10-03 17:44

- Fredun Pharmaceuticals Ltd announced the allotment of 1,82,400 Equity Shares of face value ₹10 each to 10 non-promoter allottees. - The allotment is pursuant to the conversion of 60,800 warrants into equity shares, adjusted for the 1:2 bonus issue. - Warrants were originally issued on preferential basis on December 29, 2025, at an issue price of ₹1,250 per warrant.

Governance Positive

2026-10-03 17:44

- Fredun Pharmaceuticals Ltd announced the allotment of 1,82,400 Equity Shares of face value Rs. 10/- each. - Shares are allotted to 10 non-promoter allottees upon the conversion of 60,800 warrants, adjusted for a 1:2 bonus issue. - The board meeting for the allotment was held on October 3, 2026.

Routine Neutral

2026-09-28 20:00

- Trading window for dealing in company securities will remain closed from October 1, 2026. - Closure will continue until 48 hours after the Board Meeting considering unaudited financial results for the quarter and half year ended September 30, 2026.

Ownership Positive

2026-09-22 19:06

- The Board of Directors allotted 3,61,599 Equity Shares of ₹10/- each to 10 non-promoter allottees on September 16, 2026. - These shares were issued upon the conversion of 1,20,533 warrants. - The conversion ratio was adjusted to 1:3 (3 equity shares for each warrant) due to a 1:2 Bonus Issue by the company.

Ownership Positive

2026-09-22 18:29

- Board of Directors on September 16, 2026, allotted 3,61,599 equity shares of ₹10/- each. - Shares were allotted to Non-Promoter Allottees following the conversion of 1,20,533 warrants. - This conversion incorporates the effect of a 1:2 Bonus Issue, resulting in 3 equity shares per warrant.

Business Update Positive

2026-09-22 09:21

- Fredun Pharmaceuticals acquired a 26% stake in Goodman Vetcare Pvt. Ltd., valued at ₹300 Crore. - This strategic move aims to strengthen FPL's presence in the animal health and pet-care market, targeting Goodman Vetcare's revenue to ~₹100 Crore by FY31 with pan-India expansion.

Ownership Positive

2026-09-16 20:59

- Fredun Pharmaceuticals Limited allotted 2,71,200 Equity Shares of face value Rs. 10/- each to Non-Promoter warrant holders on September 16, 2026. This was upon conversion of 90,400 warrants for which the balance consideration was paid. The warrant entitlements were adjusted due to a 1:2 Bonus Issue.

Ownership Neutral

2026-09-16 20:53

- The Board of Directors of Fredun Pharmaceuticals Limited, in its meeting on September 16, 2026, allotted 2,71,200 Equity Shares of face value Rs. 10/- each. - These shares were allotted to Non-Promoter warrant holders upon conversion of 90,400 warrants. - The conversion was adjusted due to a prior 1:2 Bonus Issue, resulting in three Equity Shares for each outstanding warrant. - The warrant holders have paid the balance consideration.

Business Update Positive

2026-09-15 10:29

- Fredun Pharmaceuticals Ltd. (FPL) is accelerating its pet wellness expansion for the 'Furlicks' brand. - The 'Furlicks' product line will expand from 6 to 22 SKUs, introducing 16 new products. - This expansion, taking the brand beyond oral strips into various pet wellness and functional nutrition formats, is planned over the next 6-9 months.

Business Update Positive

2026-09-15 09:28

- Fredun Pharmaceuticals Ltd. accelerates its pet wellness expansion. - The 'Furlicks' product line has been expanded from 6 to 22 Stock Keeping Units (SKUs).

Business Update Positive

2026-09-08 11:58

- Fredun Pharmaceuticals Ltd. acquired pet-wellness brand Furlicks from USV & Wellbeing Nutrition, entering India's high-growth pet wellness market. - Initial plans include launching 12 new SKUs, followed by 32 more, to develop a comprehensive pet-wellness platform.

Business Update Positive

2026-09-04 09:43

- Fredun Pharmaceuticals launched "PAWTALKS," a new platform for pet and animal healthcare conversations. - It aims to connect experts, pet parents, and industry leaders to share knowledge and build an informed pet care ecosystem. - The platform will feature conversations, educational videos, and community engagement on YouTube and Instagram.

Business Update Positive

2026-08-17 19:24

- Fredun Pharmaceuticals Limited's Equity Shares have been permitted to trade and admitted to dealings on the National Stock Exchange of India Limited (NSE). - Trading on NSE commences from August 17, 2026. - The company was already listed on BSE Limited.

Business Update Positive

2026-08-17 16:21

- FY27 revenue guidance of ₹800 Cr, with an expectation to overachieve. FY26 actual revenue was ₹635 Cr against a target of ₹570 Cr. - Blended revenue growth expected at 30-35% YoY for the next 3 years, driven by new age brands (35-45% YoY) and vintage business (15-20% YoY). - GX business line projected to grow 25-35% YoY for the next 5 years. - Pet care business (including Wagr.in) targeted for 40-50% growth YoY for the next 3-4 years, aiming for ₹100 Cr revenue within 3-3.5 years. Launching cat food by Q3 FY27. - Capex plan includes ₹30-40 Cr for FY27 and ₹35-45 Cr annually for the next 2 years for manufacturing expansion. - Expect EBIT margins to reach 12-13% within the next 12 quarters, with a potential sudden spike in profitability in 8-11 quarters. - Working capital inventory days targeted to reduce to 110-125 days within the next 4 quarters. - Credit rating improved from BBB to BBB+.

Business Update Neutral

2026-08-13 16:48

- Audio recording of Q1 FY27 Earnings Conference Call held on August 13, 2026, for Un-Audited Financial Results (quarter ended June 30, 2026) is available on the company's website.

Business Update Neutral

2026-08-08 19:13

- Concall Schedule - Concall Date: 13th August, 2026 - Concall Time: 11:30 a.m.

Financials Positive

2026-08-06 15:10

- Consolidated Revenue ₹128.25Cr vs ₹98.87Cr (▲29.71% YoY) - EBITDA ₹13.53Cr vs ₹7.01Cr (▲93.12% YoY) - PAT ₹11.01Cr vs ₹5.47Cr (▲101.14% YoY) - EBITDA Margin 10.55% vs 7.09% (▲346bps)

Financials Positive

2026-08-06 13:59

- Standalone Total Income ₹228.25 Cr vs ₹119.86 Cr (▲90.44% YoY) - Standalone EBITDA ₹32.78 Cr vs ₹16.99 Cr (▲92.90% YoY) - Standalone PAT ₹13.17 Cr vs ₹6.77 Cr (▲94.63% YoY) - Standalone EBITDA Margin 14.36% vs 14.18% (▲18bps)

Financials Positive

2026-08-05 11:47

- Consolidated Revenue ₹227.76Cr vs ₹119.40Cr (▲90.75% YoY) - EBITDA ₹32.25Cr vs ₹₹16.54Cr (▲95.09% YoY) - PAT ₹13.13Cr vs ₹6.77Cr (▲94.09% YoY) - EBITDA Margin 14.16% vs 13.85% (▲31bps)

Financials Positive

2026-08-05 11:39

- Consolidated Revenue ₹22,775.55 Lakhs vs ₹11,940.29 Lakhs (▲90.75% YoY) - EBITDA ₹3,274.09 Lakhs vs ₹1,699.12 Lakhs (▲92.69% YoY) - PAT ₹1,313.23 Lakhs vs ₹676.58 Lakhs (▲94.09% YoY) - EBITDA Margin 14.34% vs 14.18% (▲16bps)

Governance Neutral

2026-07-30 18:17

- Board meeting on August 05, 2026, to consider and approve unaudited financial results (Standalone and Consolidated) for the first quarter ended June 30, 2026. - Trading window for dealing in securities remains closed until 48 hours after the declaration of financial results.

Financials Positive

2026-07-17 13:07

- Fredun Pharmaceuticals Limited allotted 11,025,380 Bonus Equity Shares in a 2:1 ratio (2 new shares for every 1 existing) as of the record date July 16, 2026. - The paid-up share capital increased from ₹5,51,26,900 to ₹16,53,80,700.

539730

Fredun Pharmaceuticals Ltd

Price Chart

Filing History

Unlock Full History